modelHydralazine_1
Extends from Pharmacolibrary.Drugs.ATC.C.C02DB02_1.
Information
| name: | Hydralazine_1 | |
| ATC code: | C02DB02_1 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 2.5 | L |
| clearance: | 10 | mL/min/kg |
| other parameters in model implementation | ||
Hydralazine is a vasodilator used primarily to treat hypertension and congestive heart failure. It acts by directly relaxing vascular smooth muscle, leading to decreased peripheral resistance. Hydralazine is still approved and used clinically, often as adjunct therapy or when first-line antihypertensive agents are unsuitable.
Pharmacokinetics
Pharmacokinetic parameters from intravenous administration in healthy adults.
References
Chera-Aree, P, et al., & Wataganara, T (2020). Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. Journal of clinical pharmacology 60(12) 1662–1670. DOI:10.1002/jcph.1685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32598488
Crawford, MH, et al., & Kennedy, GT (1985). Determinants of systemic availability of oral hydralazine in heart failure. Clinical pharmacology and therapeutics 38(5) 538–543. DOI:10.1038/clpt.1985.220 PUBMED:https://pubmed.ncbi.nlm.nih.gov/4053489
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)